[go: up one dir, main page]

DK78491D0 - Interleukin-4 receptorer - Google Patents

Interleukin-4 receptorer

Info

Publication number
DK78491D0
DK78491D0 DK91784A DK78491A DK78491D0 DK 78491 D0 DK78491 D0 DK 78491D0 DK 91784 A DK91784 A DK 91784A DK 78491 A DK78491 A DK 78491A DK 78491 D0 DK78491 D0 DK 78491D0
Authority
DK
Denmark
Prior art keywords
receptors
interleukin
mammalian
dnas
products
Prior art date
Application number
DK91784A
Other languages
English (en)
Other versions
DK78491A (da
DK175583B1 (da
Inventor
David J Cosman
Linda Park
Bruce Mosley
Patricia Beckman
Carl J March
Rejean Idzerda
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DK78491D0 publication Critical patent/DK78491D0/da
Publication of DK78491A publication Critical patent/DK78491A/da
Application granted granted Critical
Publication of DK175583B1 publication Critical patent/DK175583B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK199100784A 1988-10-31 1991-04-29 DNA-sekvenser kodende for interleukin-4-receptorer, RNA komplementært til disse, rekombinant ekspressionsvektor omfattende disse DNA-sekvenser, værtscelle transfekteret med denne vektor, fremgangsmåde til fremstilling af. DK175583B1 (da)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US26504788A 1988-10-31 1988-10-31
US26504788 1988-10-31
US31943889A 1989-03-02 1989-03-02
US31943889 1989-03-02
US32615689A 1989-03-20 1989-03-20
US32615689 1989-03-20
US37092489A 1989-06-23 1989-06-23
US37092489 1989-06-23
US8904076 1989-09-18
PCT/US1989/004076 WO1990005183A1 (en) 1988-10-31 1989-09-18 Interleukin-4 receptors

Publications (3)

Publication Number Publication Date
DK78491D0 true DK78491D0 (da) 1991-04-29
DK78491A DK78491A (da) 1991-04-30
DK175583B1 DK175583B1 (da) 2004-12-13

Family

ID=27500837

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199100784A DK175583B1 (da) 1988-10-31 1991-04-29 DNA-sekvenser kodende for interleukin-4-receptorer, RNA komplementært til disse, rekombinant ekspressionsvektor omfattende disse DNA-sekvenser, værtscelle transfekteret med denne vektor, fremgangsmåde til fremstilling af.

Country Status (14)

Country Link
US (10) US5840869A (da)
EP (1) EP0367566B1 (da)
JP (1) JP2744821B2 (da)
AT (1) ATE153068T1 (da)
AU (1) AU643427B2 (da)
DE (1) DE68928043T2 (da)
DK (1) DK175583B1 (da)
ES (1) ES2103706T3 (da)
FI (1) FI106044B (da)
GR (1) GR3024271T3 (da)
IE (1) IE61013B1 (da)
IL (1) IL91705A (da)
NZ (1) NZ231189A (da)
WO (1) WO1990005183A1 (da)

Families Citing this family (285)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1991003555A1 (en) * 1989-09-07 1991-03-21 Schering Corporation Interleukin-4 receptors
DE59010933D1 (de) 1989-09-12 2003-05-08 Hoffmann La Roche TFN-bindende Proteine
AU635377B2 (en) * 1989-11-21 1993-03-18 University Of Melbourne, The Anti-inflammatory compositions and methods
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
JP3122139B2 (ja) * 1991-10-15 2001-01-09 マラーキー，ミッシェル，エフ． 後期段階炎症反応の治療用組成物
CA2124338A1 (en) * 1991-11-27 1993-06-10 Nobuyuki Harada Region of cytoplasmic domain of the human interleukin-4 receptor, as antagonists of il-4
DE4322330A1 (de) 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
DE4228839A1 (de) * 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
EP0604693A1 (en) * 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
EP0689451A4 (en) * 1993-03-19 1997-08-20 Immunex Corp PHARMACEUTICAL COMPOSITIONS COMPRISING A LIGAND COMPLEXED WITH A SOLUBLE RECEPTOR
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5591825A (en) * 1994-07-05 1997-01-07 Tularik, Inc. Interleukin 4 signal transducers
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
JP4435304B2 (ja) 1995-06-29 2010-03-17 イミュネックス・コーポレーション アポトーシスを誘導するサイトカイン
US6541604B1 (en) * 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US7078494B1 (en) * 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US6586210B1 (en) 1996-08-23 2003-07-01 Human Genome Sciences, Inc. Polynucleotides encoding T1 receptor like ligand II
US6605271B2 (en) * 1996-08-23 2003-08-12 Human Genome Sciences, Inc. T1 receptor-like ligand II and uses thereof
US6242213B1 (en) 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
ES2316173T3 (es) * 1997-10-29 2009-04-01 Genentech, Inc. Genes inducibles por wnt-1.
US6703488B1 (en) * 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
WO1999045777A1 (en) * 1998-03-10 1999-09-16 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
AU756913B2 (en) 1998-08-21 2003-01-23 Immunex Corporation Human IL-1 epsilon DNA and polypeptides
EP1939297A1 (en) 1998-09-24 2008-07-02 Pharmacia & Upjohn Company LLC Alzheimer's disease secretase
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
AU780031B2 (en) * 1998-12-14 2005-02-24 Genetics Institute, Llc Cytokine receptor chain
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US6693172B1 (en) 1999-05-27 2004-02-17 Pharmacia And Upjohn Company Double mutant alpha-7 nicotinic acetylcholine receptor
US6455290B1 (en) 1999-07-09 2002-09-24 Pharmacia Italia S.P.A. Tankyrase homolog protein (THP), nucleic acids, and methods related to the same
AU2000263446A1 (en) * 1999-07-13 2001-01-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 4 receptor alpha gene
EP1222273A2 (en) 1999-10-22 2002-07-17 PHARMACIA & UPJOHN COMPANY Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
CA2392742A1 (en) * 1999-12-10 2001-06-14 Human Genome Sciences, Inc. T1 receptor-like ligand ii and uses thereof
NZ520171A (en) 1999-12-20 2005-07-29 Immunex Corp Tweak receptor
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
US6498026B2 (en) 2000-02-25 2002-12-24 Hercules Incorporated Variant galactose oxidase, nucleic acid encoding same, and methods of using same
EP1712239A3 (en) * 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
EP1158058A1 (en) * 2000-05-19 2001-11-28 Centre National De La Recherche Scientifique Compositions and methods suitable for nucleic acid analyses
AU2001274894A1 (en) 2000-05-22 2001-12-03 Pharmacia And Upjohn Company Novel matrix metalloproteinases
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
US7259244B2 (en) 2000-06-16 2007-08-21 Nerviano Medical Sciences S.R.L. Human homologue of the DBF4/ASK1 protein, nucleic acids, and methods related to the same
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
US7067626B2 (en) 2000-07-05 2006-06-27 Pharmacia & Upjohn Company Human ion channel proteins
WO2002004009A2 (en) * 2000-07-12 2002-01-17 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
AU2002241723A1 (en) * 2000-12-21 2002-07-24 Inhale Therapeutic Systems, Inc. Storage stable powder compositions of interleukin-4 receptor
EP1434871B1 (en) 2001-09-20 2017-01-18 Immunex Corporation Selection of cells expressing heteromeric polypeptides
WO2003029436A2 (en) 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
ES2557741T3 (es) 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
DK1408106T3 (da) * 2002-10-11 2007-06-11 Sentoclone Ab Cancer immunterapi
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
CA2508880C (en) 2002-12-16 2018-02-06 Technion Research And Development Foundation Ltd. Methods of preparing feeder cells-free, xeno-free human embryonic stem cells and stem cell cultures prepared using same
JP2006517962A (ja) * 2003-01-18 2006-08-03 チルドレンズ ホスピタル メディカル センター アレルゲンによって誘導された遺伝子の調節
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1648935A2 (en) 2003-07-25 2006-04-26 Amgen Inc. Antagonists and agonists of ldcam and methods of use
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
PT2805728T (pt) * 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
ATE395358T1 (de) 2004-02-27 2008-05-15 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
WO2005087801A1 (en) 2004-03-05 2005-09-22 The Board Of Trustees Of The University Of Illinois Peptide carrier for drug delivery
US7319015B2 (en) 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
US7582442B2 (en) 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
US20060002929A1 (en) * 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
AU2005247858A1 (en) 2004-04-14 2005-12-08 Monell Chemical Senses Center Taste receptors of the T1R family from domestic dog
EA013071B1 (ru) 2004-04-23 2010-02-26 ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи Способ получения вируса репродуктивно-респираторного синдрома свиней (pprsv) и способ получения pprsv вакцины
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
NZ556788A (en) 2005-01-05 2011-03-31 Biogen Idec Inc Humanized CRIPTO binding molecules with CDRs from murine B3F6
WO2006138181A2 (en) * 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
KR20070009269A (ko) 2005-07-15 2007-01-18 한국생명공학연구원 재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자
AU2006318580A1 (en) * 2005-11-21 2007-05-31 Merck Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
AU2006328945B2 (en) * 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
RU2399382C2 (ru) * 2005-12-21 2010-09-20 Сентоклон Аб Улучшенный способ увеличения числа опухоле-реактивных т-лимфоцитов в иммунотерапии онкологических больных
WO2007071410A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating urinary bladder cancer
WO2007071389A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating disseminated cancer
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
ES2371287T3 (es) 2006-06-21 2011-12-29 Apogenix Gmbh Expresión diferencial de la citocina en cáncer humano.
EP2049147A2 (en) * 2006-07-06 2009-04-22 Apogenix GmbH Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
JP5577543B2 (ja) 2006-09-08 2014-08-27 アムジエン・インコーポレーテツド Ｉｌ−１ファミリーバリアント
CN103555651A (zh) 2006-09-13 2014-02-05 Abbvie公司 细胞培养改良
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
ES2466669T3 (es) 2006-10-02 2014-06-10 Regeneron Pharmaceuticals, Inc. Anticuerpos humanos con alta afinidad para el receptor IL-4 humano
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP2010527916A (ja) * 2007-04-23 2010-08-19 ワイス・エルエルシー Ｉｌ−１３関連障害を治療する方法および組成物ならびにその治療をモニターする方法
EA201591355A1 (ru) 2007-08-21 2016-04-29 Амген Инк. АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009081201A2 (en) * 2007-12-21 2009-07-02 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Rα) - 173
GB0803076D0 (en) 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8709096B2 (en) * 2008-04-29 2014-04-29 Proxy Biomedical Limited Tissue repair implant
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
US8052970B2 (en) 2008-06-30 2011-11-08 The Regents Of The University Of Michigan Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
SG192489A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
EP2364163B1 (en) * 2008-07-18 2016-03-16 SentoClone International AB Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer
WO2010024927A2 (en) 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
KR101431091B1 (ko) 2008-12-04 2014-08-26 한국생명공학연구원 고분비성 단백질의 스크리닝 및 재조합 단백질의 생산을 위한 융합 파트너로서 그의 용도
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2432493A1 (en) 2009-05-20 2012-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-17 polypeptides for use in the prevention or treatment of atherosclerosis
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011054916A1 (en) 2009-11-06 2011-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of atherosclerosis
ES2600879T3 (es) 2009-11-13 2017-02-13 Grifols Therapeutics Inc. Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
JP5828152B6 (ja) 2010-01-20 2018-09-19 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 血管内皮細胞バリアの完全性の保存ための方法及び医薬的組成物
WO2011127418A1 (en) 2010-04-09 2011-10-13 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
SG186875A1 (en) 2010-07-09 2013-02-28 Biogen Idec Hemophilia Inc Chimeric clotting factors
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
SG187198A1 (en) 2010-08-05 2013-03-28 Amgen Inc Dipeptides to enhance yield and viability from cell cultures
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US20130195863A1 (en) 2010-09-28 2013-08-01 Philippe Clezardin Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
MX348071B (es) 2011-03-16 2017-05-26 Amgen Inc Variantes de fc.
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2012152882A1 (en) 2011-05-10 2012-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune diseases
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2535714A1 (en) * 2011-06-16 2012-12-19 Istituto Nazionale Di Genetica Molecolare-INGM Biomarkers for autoimmune liver diseases and uses thereof
ES2788132T3 (es) 2011-07-01 2020-10-20 Amgen Inc Cultivo de células de mamífero
WO2013009971A1 (en) 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Detection and screening method and materials useful in performance thereof
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CN103917458A (zh) 2011-09-02 2014-07-09 安姆根有限公司 药物产品和分析药物产品的光暴露的方法
UA118332C2 (uk) 2011-09-22 2019-01-10 Емджен Інк. Білок, що зв'язує антиген cd27l
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
EP2596802A1 (en) 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
WO2013079487A1 (en) 2011-11-28 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
TW201329104A (zh) 2011-12-08 2013-07-16 Amgen Inc 人類ｌｃａｔ抗原結合蛋白質及其治療用途
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
DK2802606T3 (da) 2012-01-10 2018-06-25 Biogen Ma Inc Forøgelse af transport af terapeutiske molekyler hen over blod-hjerne-barrieren
PL3431492T3 (pl) 2012-04-27 2021-07-05 Novo Nordisk A/S Białka wiążące antygen ludzkiego ligandu CD30
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
IN2014DN09963A (da) 2012-06-06 2015-08-14 Inst Nat Sante Rech Med
EP2674168A1 (en) 2012-06-14 2013-12-18 PLS-Design GmbH Modulation of effector T cell responses by local depletion of complement component C3
MX366178B (es) 2012-07-19 2019-07-01 Amgen Inc Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
IL312711A (en) 2012-08-21 2024-07-01 Regeneron Pharma Methods for treating or preventing asthma by administering an il-4r antagonist
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
AR093311A1 (es) 2012-11-01 2015-05-27 Abbvie Inc Inmunoglobulinas de dominio variable dual contra el factor de crecimiento endotelial vascular (vegf) y el ligando involucrado en la señalizacion celula a celula a traves del receptor notch (dll4)
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
KR20150093775A (ko) 2012-12-07 2015-08-18 노쓰 캐롤라이나 스테이트 유니버시티 베타 헥소실-전이효소 및 이의 이용
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014159764A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
MX365501B (es) 2013-03-14 2019-06-05 Amgen Inc Eliminacion de ligandos lixiviados de purificacion de afinidad.
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
US9676851B2 (en) 2013-03-15 2017-06-13 Amgen Inc. Human PAC1 antibodies
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
CA2904722C (en) 2013-03-15 2023-01-03 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
EA201592285A1 (ru) 2013-05-30 2016-05-31 Байоджен Ма Инк. Антигенсвязывающие белки к рецептору онкостатина м
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
AU2014284235B2 (en) 2013-06-21 2019-11-21 Regeneron Pharmaceuticals, Inc. Methods for treating nasal polyposis by administering an IL-4R antagonist
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
CA3174012A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
EP3733710A1 (en) 2013-09-25 2020-11-04 Amgen, Inc Hetrodimeric v-c-fc-v-c antibody
MX2016005572A (es) 2013-10-31 2016-12-09 Amgen Inc Uso de monensina para regular la glicosilacion de proteinas recombinantes.
WO2015086727A2 (en) 2013-12-11 2015-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method for patients suffering of a cancer
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US10513723B2 (en) 2014-01-13 2019-12-24 Amgen Inc. Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins
AU2014380174B2 (en) 2014-01-29 2018-08-30 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
RU2693430C2 (ru) 2014-02-20 2019-07-02 Аллерган, Инк. Антитела к компоненту комплемента с5
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
RU2018135371A (ru) 2014-02-27 2018-12-10 Аллерган, Инк. АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
NO2785538T3 (da) * 2014-05-07 2018-08-04
MX2016014761A (es) 2014-05-16 2017-05-25 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
CN106687575B (zh) 2014-06-04 2021-04-30 美国安进公司 用于收获哺乳动物细胞培养物的方法
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
AR101875A1 (es) 2014-09-15 2017-01-18 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
IL294554B2 (en) 2014-11-14 2023-11-01 Regeneron Pharma Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
EP3221465B1 (en) 2014-11-19 2019-03-13 Amgen Inc. Quantitation of glycan moiety in recombinant glycoproteins
EP3227454B1 (en) 2014-12-01 2020-01-29 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法
CR20170359A (es) 2015-02-04 2017-11-24 Hoffmann La Roche Oligómetros antisentido de tau y usos de estos
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
EP3277722B1 (en) 2015-04-02 2021-08-18 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MX2018003183A (es) 2015-09-15 2018-08-23 Amgen Inc Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
AU2016329001A1 (en) 2015-09-22 2018-03-29 Genentech, Inc. Expression of Fc-containing proteins
CN108431026B (zh) 2015-11-02 2023-02-17 豪夫迈·罗氏有限公司 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
MY197023A (en) 2015-12-23 2023-05-22 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
NZ736234A (en) 2016-05-04 2024-12-20 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
JP7092744B2 (ja) 2016-07-22 2022-06-28 アムジエン・インコーポレーテツド Ｆｃ含有タンパク質を精製する方法
JP7584218B2 (ja) 2016-09-01 2024-11-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
KR102413592B1 (ko) 2016-10-21 2022-06-27 암젠 인크 약학적 제형 및 그의 제조 방법
WO2018090052A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
AU2018206279B2 (en) 2017-01-06 2020-09-03 Abl Bio Inc. Anti-alpha-syn antibody and use thereof
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
MA47775A (fr) 2017-03-14 2020-01-22 Amgen Inc Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CA3059731A1 (en) 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
WO2019020480A1 (en) 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
EP4464719A3 (en) 2017-08-04 2025-03-05 Amgen Inc. Method of conjugation of cys-mabs
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
MA46269B1 (fr) 2017-08-18 2024-05-31 Regeneron Pharma Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
HUE064655T2 (hu) 2017-10-30 2024-04-28 Sanofi Biotechnology IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
JP7212391B2 (ja) 2017-12-14 2023-01-25 エービーエル バイオ インコーポレイテッド ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
US10738110B2 (en) 2018-01-12 2020-08-11 Amgen Inc. PAC1 antibodies and uses thereof
AU2019243848B2 (en) 2018-03-26 2025-01-02 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
CA3099163A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Antibodies with modulated glycan profiles
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
JP2022502454A (ja) 2018-10-04 2022-01-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 認知機能を回復又は改善するための方法
WO2020074005A1 (en) * 2018-10-12 2020-04-16 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric genes
AU2019398101A1 (en) 2018-12-10 2021-06-10 Amgen Inc. Mutated piggybac transposase
CN113597328A (zh) 2019-03-21 2021-11-02 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
KR20220016139A (ko) 2019-05-30 2022-02-08 암젠 인크 항체 이량체화를 유도하기 위한 경첩 영역 조작
AU2020304671A1 (en) 2019-06-28 2022-01-20 Amgen Inc. Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
KR20220042217A (ko) 2019-08-05 2022-04-04 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
BR112022002666A2 (pt) 2019-08-13 2022-08-09 Amgen Inc Muteínas de interleucina-2 para a expansão de células t reguladoras
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
TW202132340A (zh) 2019-11-04 2021-09-01 美商安進公司 治療白血病之方法
EP4055060A1 (en) 2019-11-08 2022-09-14 Amgen Inc. Engineering charge pair mutations for pairing of hetero-igg molecules
US20230047631A1 (en) 2019-11-19 2023-02-16 Amgen Inc. Novel multispecific antibody format
CR20220341A (es) 2019-12-17 2022-08-19 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia
AU2020405230A1 (en) 2019-12-20 2022-06-23 Amgen Inc. Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3191710A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
JP2023544769A (ja) 2020-10-07 2023-10-25 アムジエン・インコーポレーテツド 多重特異性抗体の構築のためのビルディングブロックの合理的選択
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
TW202233660A (zh) 2020-10-30 2022-09-01 美商安進公司 過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充
EP4244246A1 (en) 2020-11-10 2023-09-20 Amgen Inc. Novel linkers of multispecific antigen binding domains
EP4326761A1 (en) 2021-04-20 2024-02-28 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
US20240209115A1 (en) 2021-04-29 2024-06-27 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
EP4351722A1 (en) 2021-06-10 2024-04-17 Amgen Inc. Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3
TW202328442A (zh) 2021-09-10 2023-07-16 美商安進公司 平臺宿主對ｉｇｆ—培養基之適應
MX2024003852A (es) 2021-10-05 2024-05-24 Amgen Inc Unión al receptor fc-gamma y contenido de glucanos.
KR20240128067A (ko) 2021-12-29 2024-08-23 브리스톨-마이어스 스큅 컴퍼니 랜딩 패드 세포주의 생성
WO2023172965A1 (en) 2022-03-09 2023-09-14 Amgen Inc. Optimized transfection protocol
CN119053620A (zh) 2022-03-16 2024-11-29 Inserm(法国国家健康医学研究院) 治疗传染病的新方法
TW202406572A (zh) 2022-05-02 2024-02-16 美商再生元醫藥公司 抗介白素－４受體（ｉｌ－４ｒ）抗體調配物
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
TW202409060A (zh) 2022-05-02 2024-03-01 美商再生元醫藥公司 用於降低脂酶活性之方法
EP4406973A1 (en) 2023-01-27 2024-07-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025006529A1 (en) 2023-06-27 2025-01-02 Amgen Inc. Charge pair mutations to enable correct heavy-light chain pairing
US20250027052A1 (en) 2023-07-21 2025-01-23 Amgen Inc. Vectors incorporating a combination of promoters driving selectable marker expression
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) * 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
EP0327283B1 (en) * 1988-02-02 1993-08-18 Schering Biotech Corporation Method of reducing immunoglobulin e responses
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
KR0172123B1 (ko) * 1989-03-07 1999-02-01 게르하르트 후버; 루돌프 호프만 재조합 단백질 수용체
WO1991003555A1 (en) * 1989-09-07 1991-03-21 Schering Corporation Interleukin-4 receptors
US5246701A (en) * 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
CA2124338A1 (en) * 1991-11-27 1993-06-10 Nobuyuki Harada Region of cytoplasmic domain of the human interleukin-4 receptor, as antagonists of il-4
DE4322330A1 (de) 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
EP0689451A4 (en) * 1993-03-19 1997-08-20 Immunex Corp PHARMACEUTICAL COMPOSITIONS COMPRISING A LIGAND COMPLEXED WITH A SOLUBLE RECEPTOR

Also Published As

Publication number Publication date
ES2103706T3 (es) 1997-10-01
DE68928043D1 (de) 1997-06-19
US5767065A (en) 1998-06-16
FI912064A0 (fi) 1991-04-29
US5856296A (en) 1999-01-05
AU643427B2 (en) 1993-11-18
DK78491A (da) 1991-04-30
US20030185821A1 (en) 2003-10-02
WO1990005183A1 (en) 1990-05-17
JPH02215385A (ja) 1990-08-28
IL91705A (en) 1998-12-27
US20090226472A1 (en) 2009-09-10
US7317090B2 (en) 2008-01-08
ATE153068T1 (de) 1997-05-15
FI106044B (fi) 2000-11-15
DK175583B1 (da) 2004-12-13
GR3024271T3 (en) 1997-10-31
US5717072A (en) 1998-02-10
NZ231189A (en) 1991-06-25
US20050118176A1 (en) 2005-06-02
DE68928043T2 (de) 1997-09-11
JP2744821B2 (ja) 1998-04-28
US5599905A (en) 1997-02-04
US6716587B2 (en) 2004-04-06
US5840869A (en) 1998-11-24
US6391581B1 (en) 2002-05-21
EP0367566A1 (en) 1990-05-09
IL91705A0 (en) 1990-06-10
US6548655B1 (en) 2003-04-15
IE893027L (en) 1990-04-30
AU4411389A (en) 1990-05-28
EP0367566B1 (en) 1997-05-14
IE61013B1 (en) 1994-09-07

Similar Documents

Publication Publication Date Title
DE68928043D1 (de) Interleukin-4-Rezeptoren
EP0318296A3 (en) Interleukin-1 receptors
LU90591I2 (fr) Enbrel-etanercept
DK0403114T3 (da) Interleukin-7-receptorer
DE3851035D1 (de) Interleukin-7.
DE69132937D1 (de) Typ-II-Interleukin-1-Rezeptoren
NO872988D0 (no) Pattedyr-interleukin-4.
FI945877A0 (fi) Menetelmä proteiini C:n tuottamiseksi
DK0494260T3 (da) Receptorer for granulocytkolonistimulerende faktor

Legal Events

Date Code Title Description
PUP Patent expired